Comparing SG&A Expenses: Catalent, Inc. vs Ultragenyx Pharmaceutical Inc. Trends and Insights

SG&A Expenses: Catalent vs. Ultragenyx - A Decade of Growth

__timestampCatalent, Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 201433480000010811000
Thursday, January 1, 201533730000033001000
Friday, January 1, 201635810000064936000
Sunday, January 1, 201740260000099909000
Monday, January 1, 2018462600000127724000
Tuesday, January 1, 2019512000000161524000
Wednesday, January 1, 2020577900000182933000
Friday, January 1, 2021687000000219982000
Saturday, January 1, 2022844000000278139000
Sunday, January 1, 2023831000000309799000
Monday, January 1, 2024935000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical and biotech industries, understanding the financial strategies of key players is crucial. Catalent, Inc. and Ultragenyx Pharmaceutical Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Catalent's SG&A expenses have surged by approximately 179% over this period, reflecting a strategic expansion and investment in operational capabilities. In contrast, Ultragenyx's expenses have increased by nearly 2,765%, indicating a rapid scale-up in its business operations, albeit from a smaller base.

Insights and Implications

Catalent's consistent growth in SG&A expenses suggests a steady scaling of operations, while Ultragenyx's sharp rise points to aggressive growth strategies. The data for 2024 is incomplete, highlighting the need for ongoing analysis to understand future trends. Investors and industry analysts should consider these financial trajectories when evaluating the companies' market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025